All Eyes On US Approval After Ipsen’s FOP Candidate Rejected By EU
Second Time Lucky?
The French firm’s palovarotene for fibrodysplasia ossificans progressiva received a thumbs down from the European Commission, but a positive advisory committee outcome on the other side of the pond bodes well for its second attempt at US approval.
You may also be interested in...
Just a month after an EU rejection, the French drugmaker’s oral retinoic acid receptor gamma agonist Sohonos has won a US thumbs up for the treatment of fibrodysplasia ossificans progressiva, an ultra-rare disorder that turns soft tissue into bone.
CEO David Loew tells Scrip that valuations to do deals with biotechs “are now at a reasonable level [and] we are screening companies very actively as we speak."